← All trials
NCT05584709
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Oct 31, 2025
- First posted
- Oct 18, 2022
- Last posted
- Oct 18, 2022
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sorrento Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.